Amphastar Pharmaceuticals, Inc. (AMPH) Spending and interest coverage
- R&D / revenue · 12 months: Value 12.95%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.95%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 12.95% | Research and development expense / revenue. Period ending 2026-06-30. $94.57M ÷ $730.02M × 100 ≈ 12.95% |
| Stock-based compensation / revenue · 12 months | 3.95% | Share-based compensation / revenue. Period ending 2026-06-30. $28.87M ÷ $730.02M × 100 ≈ 3.95% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 94.57M USD | Research and Development Expense |
| Revenue | 730.02M USD | |
| Stock-based compensation | 28.87M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 114.28M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $94.57M | $730.02M | $28.87M | $114.28M | (m) | 12.95% | 3.95% | (m) | (m) |
| 2026-03-31 | $92.48M | $720.53M | $28.16M | $116.74M | (m) | 12.84% | 3.91% | (m) | (m) |
| 2025-12-31 | $85.84M | $719.89M | $27.28M | $140.40M | (m) | 11.92% | 3.79% | (m) | (m) |
| 2025-09-30 | $80.67M | $723.30M | $26.70M | $149.94M | (m) | 11.15% | 3.69% | (m) | (m) |
| 2025-06-30 | $79.39M | $722.68M | $26.00M | $181.67M | (m) | 10.99% | 3.60% | (m) | (m) |
| 2025-03-31 | $76.97M | $730.66M | $25.40M | $194.70M | (m) | 10.53% | 3.48% | (m) | (m) |
| 2024-12-31 | $73.91M | $731.97M | $24.37M | $205.42M | (m) | 10.10% | 3.33% | (m) | (m) |
| 2024-09-30 | $76.19M | $723.55M | $23.36M | $214.25M | (m) | 10.53% | 3.23% | (m) | (m) |
| 2024-06-30 | $71.78M | $712.89M | $22.41M | $229.88M | (m) | 10.07% | 3.14% | (m) | (m) |
| 2024-03-31 | $70.97M | $676.21M | $21.49M | $211.56M | $35.37M | 10.50% | 3.18% | 5.98× | Reported |
| 2023-12-31 | $73.74M | $644.39M | $20.24M | $196.99M | $27.16M | 11.44% | 3.14% | 7.25× | Reported |
| 2023-09-30 | $70.56M | $601.31M | $19.92M | $180.84M | $18.23M | 11.73% | 3.31% | 9.92× | Reported |
| 2023-06-30 | $72.41M | $540.89M | $19.58M | $131.39M | $5.09M | 13.39% | 3.62% | 25.79× | Reported |
| 2023-03-31 | $78.36M | $518.64M | $18.95M | $119.32M | $1.89M | 15.11% | 3.65% | 63.16× | Reported |
| 2022-12-31 | $74.77M | $498.99M | $17.86M | $107.50M | $1.85M | 14.98% | 3.58% | 58.23× | Reported |
| 2022-09-30 | $74.82M | $484.85M | $17.41M | $93.92M | $1.49M | 15.43% | 3.59% | 63.20× | Reported |
| 2022-06-30 | $67.07M | $476.92M | $17.03M | $95.46M | $1.45M | 14.06% | 3.57% | 65.97× | Reported |
| 2022-03-31 | $62.39M | $455.12M | $18.88M | $81.19M | $1.14M | 13.71% | 4.15% | 71.47× | Reported |
| 2021-12-31 | $60.93M | $437.77M | $18.69M | $69.89M | $885.00K | 13.92% | 4.27% | 78.97× | Reported |
| 2021-09-30 | $61.78M | $412.80M | $19.17M | $48.51M | $805.00K | 14.97% | 4.64% | 60.27× | Reported |
| 2021-06-30 | $68.66M | $384.04M | $19.62M | $27.26M | $453.00K | 17.88% | 5.11% | 60.18× | Reported |
| 2021-03-31 | $66.69M | $368.18M | $20.05M | $13.78M | $402.00K | 18.11% | 5.45% | 34.28× | Reported |
| 2020-12-31 | $67.23M | $349.85M | $20.50M | $10.95M | $374.00K | 19.22% | 5.86% | 29.29× | Reported |
| 2020-09-30 | $68.74M | $337.31M | $20.46M | $7.83M | $329.00K | 20.38% | 6.07% | 23.80× | Reported |
| 2020-06-30 | $69.70M | $334.01M | $20.38M | $6.72M | $176.00K | 20.87% | 6.10% | 38.17× | Reported |
| 2020-03-31 | $69.55M | $327.25M | $17.90M | $10.61M | $165.00K | 21.25% | 5.47% | 64.32× | Reported |
| 2019-12-31 | $68.85M | $322.36M | $17.30M | $-39.00K | $119.00K | 21.36% | 5.37% | -0.33× | Reported |
| 2019-09-30 | $65.94M | $328.66M | $16.91M | $1.75M | $77.00K | 20.06% | 5.15% | 22.73× | Reported |
| 2019-06-30 | $58.68M | $324.07M | $16.52M | $1.90M | $179.00K | 18.11% | 5.10% | 10.59× | Reported |
| 2019-03-31 | $58.14M | $316.06M | $16.69M | $-2.02M | $255.00K | 18.40% | 5.28% | -7.91× | Reported |
| 2018-12-31 | $57.56M | $294.67M | $16.68M | $-8.62M | $243.00K | 19.54% | 5.66% | -35.49× | Reported |
| 2018-09-30 | $52.13M | $265.38M | $16.95M | $-11.54M | $376.00K | 19.64% | 6.39% | -30.69× | Reported |
| 2018-06-30 | $51.16M | $247.75M | $17.20M | $-17.26M | $516.00K | 20.65% | 6.94% | -33.45× | Reported |
| 2018-03-31 | $46.42M | $241.90M | $17.30M | $-12.22M | $653.00K | 19.19% | 7.15% | -18.71× | Reported |
| 2017-12-31 | $43.41M | $240.18M | $17.09M | $-895.00K | $826.00K | 18.08% | 7.11% | -1.08× | Reported |
| 2017-09-30 | $44.30M | $243.32M | $16.43M | $-3.74M | $746.00K | 18.21% | 6.75% | -5.01× | Reported |
| 2017-06-30 | $43.98M | $249.62M | $15.82M | $4.88M | $763.00K | 17.62% | 6.34% | 6.39× | Reported |
| 2017-03-31 | $43.84M | $252.47M | $15.72M | $13.02M | $831.00K | 17.37% | 6.23% | 15.67× | Reported |
| 2016-12-31 | $41.20M | $255.16M | $15.12M | $15.69M | $1.02M | 16.15% | 5.93% | 15.32× | Reported |
| 2016-09-30 | $37.24M | $268.53M | $13.48M | $34.57M | $1.17M | 13.87% | 5.02% | 29.45× | Reported |
| 2016-06-30 | $38.64M | $268.18M | $13.16M | $25.03M | $1.13M | 14.41% | 4.91% | 22.25× | Reported |
| 2016-03-31 | $38.88M | $254.00M | $12.86M | $4.44M | $1.03M | 15.31% | 5.06% | 4.31× | Reported |
| 2015-12-31 | $37.06M | $251.52M | $11.68M | $-6.90M | $987.00K | 14.74% | 4.65% | -6.99× | Reported |
| 2015-09-30 | $36.05M | $230.48M | $11.07M | $-28.29M | $233.00K | 15.64% | 4.80% | -121.43× | Reported |
| 2015-06-30 | $33.52M | $226.33M | $10.54M | $-32.36M | $505.00K | 14.81% | 4.66% | -64.08× | Reported |
| 2015-03-31 | $28.79M | $221.48M | $9.18M | $-23.27M | $770.00K | 13.00% | 4.14% | -30.23× | Reported |
| 2014-12-31 | $28.43M | $210.46M | $8.33M | $-17.98M | $609.00K | 13.51% | 3.96% | -29.53× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $222.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $33.02M | $229.68M | $6.09M | $17.49M | $958.00K | 14.38% | 2.65% | 18.26× | Reported |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $31.16M | $204.32M | $6.67M | $25.40M | $784.00K | 15.25% | 3.27% | 32.39× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |